Success Metrics

Completion Rate
0%(0/4)
Active Trials
0(0%)
Terminated
4(22%)

Phase Distribution

Ph phase_1
15
83%
Ph phase_2
3
17%

Phase Distribution

15

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
15(83.3%)
Phase 2Efficacy & side effects
3(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 18 finished

Non-Completion Rate

100.0%

18 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Terminated(18)

Detailed Status

Withdrawn14
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 115 (83.3%)
Phase 23 (16.7%)

Trials by Status

terminated422%
withdrawn1478%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT03169764Phase 1

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03169790Phase 1

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Withdrawn
NCT03175666Phase 1

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Withdrawn
NCT03647423Phase 1

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Withdrawn
NCT03167164Phase 1

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Withdrawn
NCT03574649Phase 2

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Withdrawn
NCT03167177Phase 1

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03554109Phase 2

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

Withdrawn
NCT03197571Phase 1

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03563144Phase 2

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Withdrawn
NCT03197584Phase 1

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Withdrawn
NCT03169777Phase 1

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Withdrawn
NCT03169738Phase 1

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Withdrawn
NCT03563157Phase 1

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Terminated
NCT03586869Phase 1

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Terminated
NCT03387085Phase 1

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Terminated
NCT03387111Phase 1

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Terminated
NCT03563170Phase 1

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Withdrawn

All 18 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
18